May 14, 2019 5:59pm
In quarterly reporting, how many times will investors condone Biostage’s (OTCQB: BSTG) CEO McGorry and CFO McNaughton misinforming shareholders while manipulating the quarterly balance sheet and - not the first time? The $1.1 M cash position is actually a negative; as accounts payable, accrued and operating lease liabilities erase the “current” asset position! Also why is the IND filing being pushed back to the 2nd half; it was due two (2) or was it three (3) years ago! By the way, what say this board of directors (BOD)?
Pre-open indications: 5 HITs and 1 MISS
Q1 results: Neuralstem (CUR) and Cesca Therapeutics (KOOL)
Don’t get comfortable, today’s market impacts Wednesday; If you were a subscriber … you would understand why!
Members only. Please login.